Breast Cancer Res Treat (2012) 134:943–955 21. Labrecque L, Lamy S, Chapus A et al (2005) Combined inhibi- tion of PDGF and VEGF receptors by ellagic acid, a dietary- derived phenolic compound. Carcinogenesis 26:821–826 22. Lee KH, Choi HR, Kim CH (2005) Anti-angiogenic effect of the seed extract of Benincasa hispida Cogniaux. J Ethnopharmacol 97:509–513 23. Losso JN, Bansode RR, Trappey A 2nd et al (2004) In vitro anti- proliferative activities of ellagic acid. J Nutr Biochem 15:672–678 24. Shyu KG, Tsai SC, Wang BW et al (2004) Saikosaponin C induces endothelial cells growth, migration and capillary tube formation. Life Sci 76:813–826 25. Auerbach R, Lewis R, Shinners B et al (2003) Angiogenesis assays: a critical overview. Clin Chem 49:32–40 26. Wen W, Lu J, Zhang K et al (2008) Grape seed extract inhibits angiogenesis via suppression of the vascular endothelial growth factor receptor signaling pathway. Cancer Prev Res (Phila) 1:554–561 27. Zhang S, Cao Z, Tian H et al (2011) SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res 17:4439–4450 28. Colavitti R, Pani G, Bedogni B et al (2002) Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 277:3101–3108 29. Price JE, Polyzos A, Zhang RD et al (1990) Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50:717–721 30. Wang D, Stockard CR, Harkins L et al (2008) Immunohisto- chemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem 83:179–189 955 31. Harris PA, Cheung M, Hunter RN 3rd et al (2005) Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEG- FR-2 kinase inhibitors. J Med Chem 48:1610–1619 32. Sekiguchi Y, Nakaniwa T, Kinoshita T et al (2009) Structural insight into human CK2a in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett 19:2920–2923 33. Fox SB, Generali DG, Harris AL (2007) Breast tumour angio- genesis. Breast Cancer Res 9:216 34. Paz K, Zhu Z (2005) Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Front Biosci 10:1415–1439 35. Gingras D, Lamy S, Be´liveau R (2000) Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins. Biochem J 348:273–280 36. Jung MH, Lee SH, Ahn EM et al (2009) Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 30:655–661 37. Chung BH, Lee JJ, Kim JD et al (2010) Angiogenic activity of sesamin through the activation of multiple signal pathways. Biochem Biophys Res Commun 391:254–260 38. Gabriele B, Rolf B, Gerald M et al (2000) Matrix metallopro- teinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744 39. Shinkaruk S, Bayle M, La¨ın G et al (2003) Vascular endothelial cell growth factor (VEGF), an emerging target for cancer che- motherapy. Curr Med Chem Anticancer Agents 3:95–117 123